Beruflich Dokumente
Kultur Dokumente
Accepted Article
Colposcopic biopsy findings among women with either HPV-16 only or HPV-18
Ibrahim Yalcin 1*, Mustafa E. Sari 1, Hanifi Sahin 1, Murat Gultekin 2, Tayfun Gungor 1,
Mehmet M. Meydanli 1
1
Department of Gynecologic Oncology, Zekai Tahir Burak Women’s Health Research and
2
Department of Gynecologic Oncology, Faculty of Medicine, Hacettepe University, Ankara,
Turkey
*
Corresponding author: Ibrahim Yalcin
Department of Gynecologic Oncology, Zekai Tahir Burak Women’s Health Research and
Talatpaşa Bulvarı No: 128 Posta kodu 06230, Samanpazarı, Altındağ, Ankara, Turkey.
E-mail: ibrahimyalcin73@gmail.com
This article has been accepted for publication and undergone full peer review but has not
been through the copyediting, typesetting, pagination and proofreading process, which may
lead to differences between this version and the Version of Record. Please cite this article as
doi: 10.1002/ijgo.12652
Synopsis: High-grade squamous intraepithelial lesions were increased among women with
normal cervical cytology and HPV-16 only versus women with normal cervical
Abstract
Objective: To compare colposcopic biopsy results among women with normal cervical
cytology who had positive test results for either HPV-16 only or HPV-18 only.
Health Research and Training Hospital, Ankara, Turkey, between July 1, 2015, and
October 31, 2017. Colposcopic biopsy results were compared among women in the
Results: Women who had HPV-16 only were more likely to be smokers than women with
HPV-18 only (P=0.003). By contrast, women with HPV-18 only were more likely to be aged
at least 45 years than women who had HPV-16 only (P=0.038). High-grade squamous
intraepithelial lesions were detected more frequently in the HPV-16 only group (51 [27.6%])
than in the HPV-18 only group (4 [9.3%]; P=0.010. By contrast, no between-group difference
was found for the rate of invasive cervical cancer, which was detected in 1 (0.5%) woman in
the HPV-16 only group and 1 (2.3%) woman in HPV-18 only group (P=0.342).
increased among women with HPV-16 only, this finding did not influence the rate of
invasive cervical cancer when compared with women in the HPV-18 only group.
times more prevalent than HPV-18 [1], which in turn ranks as the second most frequently
detected type of HPV in cervical cancer [2]. In addition, HPV-16 and HPV-18 were the most
common HPV types among females with normal cervical cytology findings in the pre-HPV
Persistent infection with HPV-16 and/or HPV-18 is the most important determinant
for the development of precancerous lesions and cervical cancer [2]. In the USA, the
greater when compared with other types of high-risk HPV (17% and 14% vs 3%,
who have normal cervical cytology but positive HPV-16 or HPV-18 test results
should be referred for immediate colposcopy [5]. To date, few studies have assessed
the colposcopic biopsy results of women with positive tests results for HPV-16 or
HPV-18 [6–10]. Most of the available studies demonstrated increased rates of CIN 3
among patients with HPV-16 compared with patients with HPV-18 [7–10]. However,
the women enrolled in these studies were not identified as having a single type of
HPV. Of note, only Monsonego et al. [9]—who analyzed data from the baseline
phase of the Addressing the Need for Advanced HPV Diagnostics (ATHENA) trial—
reported colposcopic biopsy results among patients with HPV-16 and HPV-18 with
women with normal cervical cytology who have either HPV-16 only or HPV-18 only
has been running in Turkey since 2014 [11]. The aim of the present study was to compare
colposcopic biopsy results of women in Turkey with normal cervical cytology who had either
Oncology, Zekai Tahir Burak Women’s Health Research and Training Hospital, Ankara,
Turkey, between July 1, 2015, and October 31, 2017. The Local Ethics Committee of Zekai
Tahir Burak Women’s Health Research and Training Hospital approved the present study
on June 29, 2015 (approval number: 08). All participants provided written informed consent
for the performance of diagnostic and surgical procedures, as well as the use of their clinical
Since January 2014, women in Turkey who are aged 30–65 years have been encouraged to
front-line healthcare personnel (i.e. general practitioners [GPs] and KETEM screening
centers—facilities for the early screening and diagnosis of cancer). The present study was
Kits for collecting HPV DNA samples (Hybrid Capture 2; Qiagen, Hilden, Germany) were
sent to local healthcare authorities in each province by central laboratories based in Ankara
and Istanbul. The local authorities then made these kits available to GPs and KETEM
screening centers. Every woman who attended screening provided two samples, one for
previously, the cytology tests were interpreted by four pathologists at a central laboratory
[11]. The second sample was obtained using a separate brush and placed into 5 mL of the
standard transport medium from the Hybrid Capture 2 collection kit for HPV DNA testing. As
previously described, genotyping was carried out using the CLART HPV kit (Genomica,
Madrid, Spain) for any patient who had a positive non-specific HPV test result [11]. The
specimens were evaluated at the two central laboratories in Ankara and in Istanbul. The
specimens were tracked and the results delivered online using a fully automated operational
system.
Inclusion criteria for the present study were normal cervical cytology and a positive test
result for either HPV-16 only or HPV-18 only. Women with multiple HPV positivity (i.e. HPV-
16 plus HPV-18; HPV-16 plus another type of high-risk HPV; or HPV-18 plus another type of
high-risk HPV) were excluded. Other exclusion criteria were a history of cervical histology
anomaly or cancer at any site; HIV infection; immunosuppressive treatment; and HPV
vaccination.
Colposcopy was provided free of charge at a post-screening diagnostic center for any
patient with a positive result for either HPV-16 only or HPV-18 only. At least one such center
is located in each of the 81 provinces of Turkey. The outpatient colposcopy clinic at Zekai
Tahir Burak Women’s Health Research and Training Hospital is one of the two post-
screening diagnostic centers in Ankara province. Women residing in the east of this province
who had positive HPV test results were referred to this clinic by GPs responsible for that
region.
optics (MIKRO, Prague, Czech Republic) was used for these procedures. The cervix was
Colposcopic findings were described using the criteria of the International Federation of
Cervical Pathology and Colposcopy [12]. The colposcopy result was accepted as adequate if
the cervix could be completely evaluated and was not blocked by bleeding, inflammation, or
scarring. The squamocolumnar junction was assessed to be completely apparent when 360°
of the junction could be visualized. A colposcopically directed biopsy was obtained from the
area with the greatest degree of abnormal appearance, after which endocervical curettage
(ECC) was performed. If there were no obvious abnormal colposcopy findings, two random
cervical punch biopsies were taken from the transformation zone, and then ECC was carried
out. If unsatisfactory colposcopy findings were obtained, two random cervical punch biopsies
were taken at 12 o’clock and 6 o’clock (the midpoint of the anterior and posterior lip of the
cervix, respectively), and ECC was then carried out. Institutional policy was to perform
cervical punch biopsy and ECC for cases of high-risk HPV DNA positivity.
Cervical conization was conducted when the initial work-up revealed high-grade squamous
intraepithelial lesions. The final histologic statistical comparison was made on the most
severe histologic findings obtained from cervical punch biopsy, ECC, or cervical
pathologists reviewed the surgical specimens in a masked manner. The final diagnosis was
made using standard criteria for the Lower Anogenital Squamous Terminology [13].
education; parity; smoking habit; and contraceptive use, were recorded at entry into the
present study.
The data were analyzed using SPSS version 22 (IBM, Armonk, NY, USA). Descriptive
statistics were used for the demographic data. Values were analyzed using the Mann–
Whitney U, χ2, or Fisher exact tests, as appropriate. A P value of less than 0.05 was
3. Results
In all, 723 women aged 30–65 years were considered for eligibility for the present study;
of these, 228 women had positive test results for either HPV-16 only or HPV-18 only
and were included in the study. The median age of these patients was 44 years.
Table 1 outlines the demographic characteristics and colposcopy findings of the HPV-16
only group (n=185) versus the HPV-18 only group (n=43). Women who had HPV-16 only
were more likely to be smokers than were women with HPV-18 only (P=0.003). By contrast,
women with HPV-18 only were more likely to be aged at least 45 years than women who
had HPV-16 only (P=0.038) No other statistically significant between-group differences were
The final pathology results for each group and for each diagnostic procedure are
shown in Table 2. In the HPV-16 only group, seven women were diagnosed as having
HSILs only by ECC. The two groups of patients were compared in terms of HSILs diagnoses
respectively; P=0.010.
and 10 women had positive surgical cone margins. Eight of these patients underwent
reconization and two underwent simple hysterectomy. No residual disease was found
After the cold-knife conization, there was one invasive cervical cancer diagnosis in each
group who were initially diagnosed as HSILs. No between-group difference was found for
the rate of invasive cervical cancer (Table 2). One (0.5%) woman in the HPV-16 only group
and one (2.3%) woman in the HPV-18 only group were diagnosed with this condition
(P=0.342).
4. Discussion
To the best of our knowledge, the present study was the first to compare colposcopic biopsy
results among women with normal cervical cytology who had either HPV-16 only or HPV-18
only. The findings indicated that women in HPV-16 only group were more likely to have high-
grade lesions than were those in the HPV-18 only group. By contrast, no between-group
ATHENA data, the risk of CIN 2 or worse was increased among women in all age groups
who had HPV-16 versus women who had HPV-18 (31.5% vs 4.3%, respectively.) [10].
significance on cytologic examination. Wright et al. [15] evaluated HPV-16 and HPV-18
genotypes for the triage of women with high-risk HPV but normal cervical cytology. The
absolute risk of CIN 3 or worse was 11.7% (95% confidence interval 7.9–15.8) among
women with HPV-16 and 5.7% (95% confidence interval 1.7–9.9) among women with HPV-
18. Unfortunately, however, these investigators did not state the absolute number of patients
in each group. Schiffman et al. [17] reported a 3-year cumulative risk of CIN 3 or worse
among a group of 18 000 women (age ≥30 years) with normal cervical cytology and a
positive high-risk HPV test result. The risk was 10.6% in the HPV-16 group versus 5.9% in
Table 3 summarizes data from both published studies that have reported biopsy results
among women with HPV-16 and HPV-18, irrespective of the cervical cytology findings [6–
10], and the present study. Monsonego et al. [9] reanalyzed the ATHENA data on
genotyping of the participants with normal cervical cytology (age ≥30 years). The rate of CIN
3 or worse was 8.2% (31 of 380) among women with HPV-16 versus 4.7% (8 of 169) among
women with HPV-18. By contrast, the rates in the present study were 28.1% and 11.6%,
respectively. Monsonego et al. [9] detected invasive cervical cancer in only one woman
included in the ATHENA study. This patient had HPV-18 and had normal cervical cytology.
In addition, McKenna et al. [6] did not report any invasive cervical cancer among women
who had HPV-16 or HPV-18. Similarly to the study of Monsonego et al. [9], the present study
found only two patients had invasive cervical cancer, one (0.5%) in the HPV-16 only group
and one (2.3%) in the HPV-18 group; however, this difference was not statistically
had HPV-16, respectively, and invasive cervical cancer in (2.6%) and 17 (9.3%) patients
with HPV-18, respectively. Unfortunately, both Lagos et al. [7] and Zhang et al. [8] did not
Kurman et al. [18] first investigated individual distribution of HPV-16 and HPV-18 in various
grades of CIN and invasive squamous carcinoma. A marked difference was found regarding
(3% vs. 22%; P<0.001). Consequently, it was suggested that HPV-18 might play a role in the
development of rapidly progressive cervical cancer. Woodman et al. [19] evaluated cytologic
anomalies that occurred subsequent to infection with HPV-16 or HPV-18. The acquisition
time of such abnormalities was not associated with the type of HPV infection (P=0.88).
Therefore, these investigators were unable to support the aggressive nature of HPV-18-
associated anomalies, a conclusion that was in line with the findings of both the present
Strengths of the current study included the fact that a specific commercial kit was used for
HPV DNA genotyping to ensure that the analysis included patients who had HPV-16 only or
HPV-18 only. This approach was important because, although HPV-16 and HPV-18 are
separate genetic species, some data suggested that prevalent HPV types can influence
each other [20]. In addition, only women with normal cervical cytology were included in the
present study, which was performed in the context of a nationwide cervical cancer screening
program based on HPV DNA. Finally, the current study was one of the largest series of
patients with normal cervical cytology and either HPV-16 only or HPV-18 only that has
Nonetheless, the present study had some limitations. The inadequate tissue obtained by
ECC might have influenced the high-grade biopsy rates among both groups. Likewise, the
small number of patients in the HPV-18 only group might have influenced the histopathologic
outcomes. Causation could not be proven from the current smoking status data as the high
rate recorded in the HPV-16 only group might have resulted in selection bias. Finally, data
In conclusion, the present study findings are likely to contribute to the limited body of
evidence on this topic and have some important clinical implications. Although the risk of
high-grade squamous intraepithelial lesions was increased among women with HPV-16
only, this finding did not influence the rate of invasive cervical cancer when
compared with women who had HPV-18 only. This observation might help to inform
the future direction of the Turkish cervical cancer screening program. Further virology
and clinical studies are now required to determine differences in the natural history of
cervical cancer associated with infection by either HPV-16 only or HPV-18 only.
Author contributions
IY contributed to data collection, data analysis, data interpretation, and writing the
manuscript. MES contributed to the design of the study, data collection, data analysis, and
revising the manuscript. HS contributed to data collection, data analysis, and revising the
Conflicts of interest
References
[1] Wheeler CM, Hunt WC, Cuzick J, et al.: A population-based study of human
papillomavirus genotype prevalence in the United States: baseline measures prior to mass
[2] de Sanjose S, Quint WG, Alemany L, et al.: Human papillomavirus genotype attribution in
2010;11(11): 1048-1056.
[3] Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S: Cervical human
[4] Khan MJ, Castle PE, Lorincz AT, et al.: The elevated 10-year risk of cervical precancer
and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility
of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97(14): 1072-1079.
[5] Massad LS, Einstein MH, Huh WK, et al.: 2012 updated consensus guidelines for the
management of abnormal cervical cancer screening tests and cancer precursors. Obstet
[7] Lagos M, Van De Wyngard V, Poggi H, et al.: HPV16/18 genotyping for the triage of HPV
positive women in primary cervical cancer screening in Chile. Infect Agent Cancer 2015;10:
43.
[8] Zhang Q, Zhao M, Cao D, et al.: Assessment of the effectiveness of HPV16/18 infection
referred for colposcopy in cervical cancer screening in Northwest of China. J Med Virol
2018;90(1): 165-171.
[9] Monsonego J, Cox JT, Behrens C, et al.: Prevalence of high-risk human papilloma virus
genotypes and associated risk of cervical precancerous lesions in a large U.S. screening
population: data from the ATHENA trial. Gynecol Oncol 2015;137(1): 47-54.
[10] Stoler MH, Wright TC, Jr., Sharma A, et al.: The interplay of age stratification and HPV
testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study.
[11] Gultekin M, Zayifoglu Karaca M, et al.: Initial results of population based cervical cancer
screening program using HPV testing in one million Turkish women. Int J Cancer
2018;142(9): 1952-1958.
[12] Bornstein J, Bentley J, Bosze P, et al.: 2011 colposcopic terminology of the International
Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2012;120(1): 166-172.
[13] Darragh TM, Colgan TJ, Thomas Cox J, et al.: The Lower Anogenital Squamous
consensus recommendations from the College of American Pathologists and the American
Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013;32(1): 76-115.
[15] Wright TC, Jr., Stoler MH, Sharma A, et al.: Evaluation of HPV-16 and HPV-18
genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin
[16] Kjaer SK, Frederiksen K, Munk C, Iftner T: Long-term absolute risk of cervical
[17] Schiffman M, Burk RD, Boyle S, et al.: A study of genotyping for management of human
2015;53(1): 52-59.
[18] Kurman RJ, Schiffman MH, Lancaster WD, et al.: Analysis of individual human
papillomavirus types in cervical neoplasia: a possible role for type 18 in rapid progression.
[19] Woodman CB, Collins S, Rollason TP, et al.: Human papillomavirus type 18 and rapidly
Characteristic HPV-16 only group (n=185) HPV-18 only group (n=43) P value b
Accepted Article
Age, y 43 (30–66) 47 (32–66) 0.011
Parity 0.080
Colposcopic findings
c
Inadequate 8 (4.3) 2 (4.6) >0.99
Normal Inadequ Koilocyt LSI HSI Normal Koilocyt LSI HSI Invasiv
and/or ate osis L L and/or osis L L e
inflamma tissue inflamma cervical
tion tion cancer
Stoler et al. 47 NA 8 5 17 NA 1 NA
b
[10] (17.0) (10.6) (5.8)
McKenna 38 NA 11 6 18 NA 6 6
c
et al. [6] (28.9) (15.7) (33.3) (33.3)